Last reviewed · How we verify
NCT04729374
COVID-19 Vaccine Induced Adaptive Immune Responses
trial in SARS-CoV-2 in 200 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 27 January 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Conditions studied
- SARS-CoV-2 — all drugs for SARS-CoV-2 →
- Vaccine — all drugs for Vaccine →
- COVID-19 — all drugs for COVID-19 →
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Who can join
Adults 18 to 59, any sex, with SARS-CoV-2 or Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)，resulting in more than 82 million confirmed cases and caused around 1.8 million deaths, as of 2 January 2021. The ongoing pandemic still poses unprecedented global threat to public health system worldwide. On December 31, 2020, the joint prevention and control agency of China Council announced that Sinopharm SARS-CoV-2 inactivated vaccine had been conditionally approved by National Medical Products Administration, and the protection rate was 79.34%. So far, more than 198 vaccines were currently in preclinical or clinical development. The investigators aimed to initiate an observational cohort of healthy individuals injected with SARS-CoV-2 Vaccine, which will perform a longitudinal, comprehensive analysis of the SARS-CoV-2 vaccine Induced adaptive immune responses.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine.
Chen Y, Yin S, Tong X, Tao Y, et al · · 2022 · cited 70× · PMID 34715346 · DOI 10.1016/j.cmi.2021.10.006 -
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y, Chen L, Yin S, Tao Y, et al · · 2022 · cited 51× · PMID 35608053 · DOI 10.1080/22221751.2022.2081614 -
Coronavac inactivated vaccine triggers durable, cross-reactive Fc-mediated phagocytosis activities.
Wang L, Li C, Li W, Zhao L, et al · · 2023 · cited 7× · PMID 37309826 · DOI 10.1080/22221751.2023.2225640 -
A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
Tao Y, Ma M, Hu F, Li M, et al · · 2022 · cited 6× · PMID 36384440 · DOI 10.1186/s12865-022-00532-1 -
A Longitudinal Study of Humoral Immune Responses Induced by a 3-Dose Inactivated COVID-19 Vaccine in an Observational, Prospective Cohort
Tao Y, Ma M, Li M, Geng Y, et al · · 2022 · DOI 10.2139/ssrn.4046472
Verify or expand the search:
- PubMed search for NCT04729374
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV-2
Currently open trials in the same condition.
- NCT07266558 — A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without Hig · Phase 4 · recruiting
- NCT06684379 — Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Treatment of A · Phase 1, PHASE2 · recruiting
- NCT06585241 — A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations · Phase 4 · recruiting
- NCT05876377 — Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data · active not recruiting
- NCT05799651 — Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults · Phase 1 · active not recruiting
Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials
Trials by the same sponsor.
- NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
- NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
- NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04729374 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Last refreshed: 5 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04729374.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing